

SUBJECT INDEX

A

- Abdominal pain: in pheochromocytoma, May 15
Abrin: and human tumor cloning assay, Dec. 19
Acquired immune deficiency syndrome (*see AIDS*)
Addison's disease: and hypercalcemia, Nov. 12
Adenocarcinoma with clear cell, Sept. 28
embryonal, Sept. 28
endometrium, June 16
of intestine, radioresponsiveness of, Oct. 16-19
Adenoma: and hyperparathyroidism, Nov. 23-24
Adenosine monophosphate, cyclic: and pheochromocytoma (in rat), May 75
Adrenal pheochromocytoma: angiography of, May 46
Adrenergic blockade: in pheochromocytoma, May 53-55
 β -Adrenergic blocking agents: in hyperparathyroidism, Nov. 33
 β Adrenergic receptors: desensitization by pheochromocytoma (in rat), May 72-76
AIDS, Jan. 4-39
abnormalities in major, Jan. 8
profile, Jan. 7-15
in Africa, equatorial, Jan. 20-22
comparison with U.S., Jan. 21-22
breakdown by risk group and sex, Jan. 6
in children, Jan. 19-20
classic syndrome, Jan. 5-7
directions in, Jan. 33-34
epidemiologic update, Jan. 5-7
immunologic defects, Jan. 7-8
infections, opportunistic, Jan. 9-11
Kaposi's sarcoma in, Jan. 11-15
major diseases, Jan. 6
manifestations, prodromal, Jan. 14-15
mortality rates, Jan. 6
prevention, primary, prospects for, Jan. 31-33
transmission, Jan. 15-22
by blood and blood products, Jan. 18-19
to heterosexual partners, Jan. 17-18
spread in homosexual risk population, Jan. 15-17
tumors in, Jan. 14
virus causing, probable, isolation of, Jan. 22-25
Alkylating agents: and secondary leukemias associated with ovarian cancer, Feb. 26
Alpha-fetoprotein normal range, in infant, Sept. 11
teratoma and, in infant and children, Sept. 10-12
Alpha-interferon, Dec. 24
Anesthesia: for neck dissection, Aug. 13-14
Angiography: of pheochromocytoma in adrenal, May 46
Anthracenes: and human tumor cloning assay, Dec. 25-26
Anthracycline-analogues: and human tumor cloning assay, Dec. 24
Anticoagulants: in colorectal cancer, Oct. 10-11
Antitumor agents: screening for, and human tumor cloning assay, Dec. 22-26
Anus: cancer, survival, Oct. 7
Anxiety: in pheochromocytoma, May 15
APUD system, July 6
APUDoma, July 4
ectodermal origin of, May 29
major, list of, July 5
pheochromocytoma and, May 28-29
Arteriography of parathyroid, Nov. 25
of sacrococcygeal teratoma, in newborn, Sept. 21
Assay (*see Cloning assay, human tumor*)

B

- Beta-adrenergic blocking agents: in hyperparathyroidism, Nov. 33
Beta adrenergic receptors: desensitization by pheochromocytoma (in rat), May 72-76

- Beta-interferon, Dec. 24
- Bisantrene: and human tumor cloning assay, Dec. 25
- Bladder
- cancer after cyclophosphamide, Feb. 34-35
 - tumor, and pheochromocytoma, May 21-22
- Blockade: adrenergic, in pheochromocytoma, May 53-55
- Blocking agents: β -adrenergic, in hyperparathyroidism, Nov. 33
- Blood
- AIDS transmission by, Jan. 18-19
 - pressure in pheochromocytoma alterations, May 16-19
 - after hypophysectomy (in rat), May 64-72
 - (in rat), May 73
 - sampling, central venous, in pheochromocytoma, May 50-51
 - stool occult blood testing, Apr. 34
- Bone
- cancer mortality, Mar. 67
 - disease in hyperparathyroidism, Nov. 16
- Bradycardia: in pheochromocytoma, May 19
- Brain: cancer mortality, Mar. 71
- Breast
- cancer, Apr. 17-23
 - awareness, Apr. 20-21
 - human tumor cloning assay and, Dec. 30-31
 - human tumor cloning assay and, survival, Dec. 36-38
 - incidence, Apr. 17-18
 - leukemia and, treatment-related, Feb. 24
 - nursing interventions, Apr. 19-23
 - pleural effusions after, malignant, June 15
 - risk factors, Apr. 18-19
 - signs and symptoms, Apr. 19
 - surgery of, trends in, Mar. 16
 - carcinoma, and human tumor cloning assay, Dec. 30
 - self-examination technique, Apr. 19
 - why and how of, Apr. 23
- C
- Calcium: homeostasis, regulation of, Nov. 6-7
- cAMP: and pheochromocytoma (in rat), May 75
- Cancer
- anus, survival, Oct. 7
 - bladder, after cyclophosphamide, Feb. 34-35
 - breast (see Breast, cancer)
 - cervix (see Cervix, cancer)
 - chemicals causing, Feb. 10
 - chemotherapy causing (in animals), Feb. 12
 - after chemotherapy of nonmalignant disease, Feb. 11-14
 - classification (see Classification)
 - colon (see Colorectal cancer)
 - colorectal (see Colorectal Cancer)
 - connective tissue, mortality, Mar. 69
 - data (see Data)
 - detection, Apr. 4-42
 - environmental factors in, Mar. 38
 - head, and human tumor cloning assay, Dec. 31
 - survival, Dec. 38, 39
 - hospital cancer programs (see Hospital cancer programs)
 - hypercalcemia and, Nov. 9-10
 - hyperparathyroidism and, Nov. 24-25, 41-43
 - immunosuppression and, Feb. 6-8
 - incidence (see Incidence of cancer)
 - Kulchitsky cell (see Kulchitsky cell cancer)
 - lung (see Lung, cancer)
 - mortality (see Mortality)
 - neck dissection for, Aug. 3-34
 - neck, and human tumor cloning assay, Dec. 31
 - survival, Dec. 38, 39
 - oral cavity (see Oral cavity cancer)
 - ovaries (see Ovaries, cancer)
 - prevention, Apr. 4-42
 - nutrition and, Apr. 37-39
 - primary, solid tumors after, Feb. 33-34
 - pyriform sinus, laryngopharyngectomy in, Aug. 29
 - radiation causing, Feb. 8-9
 - rectum (see Colorectal cancer)
 - risk
 - assessment, and medical history, Apr. 5-7
 - profile, Apr. 8-11
 - screening examination, Apr. 6
 - second
 - after chemotherapy, Feb. 4-43
 - after radiation, Feb. 35-37
 - skin (see Skin, cancer)

- statistics (*see* Statistics)
 surveillance in patient data system, Mar. 9–10
 survival rates, by site or disease and geographic region, Mar. 17
 testes (*see* Testes, cancer)
 tissues, stem cell model of, Dec. 6
 treatment-related, cytogenetics of, Feb. 14–16
 viruses associated with, Feb. 7
 Capillaries: human tumor cloning assay in, Dec. 8–9
 Capillary system: tumor colony formed in, Dec. 9
 Carcinoembryonic proteins: and teratoma, Sept. 10–13
 Carcinogenesis: chemical, Feb. 9–11
 Carcinogenic: chemotherapy as, Feb. 14
 Carcinoid
 atypical, July 4
 tumor, July 3
 (*See also* Kulchitsky cell cancers I and II)
 Carcinoma
 adenocarcinoma (*see* Adenocarcinoma)
 breast, and human tumor cloning assay, Dec. 30
 colorectal (*see* Colorectal carcinoma)
 Kulchitsky cell (*see* Kulchitsky cell carcinoma)
 lung (*see* Lung, carcinoma)
 ovaries, risk of second tumors after treatment, Feb. 33
 parathyroid (*see* Parathyroid, carcinoma)
 rectum (*see* Rectum, carcinoma)
 thyroid, neck dissection in, Aug. 27
 modifications of, Aug. 26
 Cardiac (*see* Heart)
 Care: national patient care evaluation studies, Mar. 16
 Carminomycin: and human tumor cloning assay, Dec. 24–25
 Catecholamines
 biosynthesis, May 5–6
 catabolism, May 7–8
 content of two tumors and chromatin granules, May 10
 after hypophysectomy (in rat), May 64–72
 metabolism
 pathway, May 8
 in pheochromocytoma (in rat), May 77–79
 -O-methyltransferase (in rat), May 78
 pheochromocytoma and, May 5–8
 diagnosis, May 39–41
 (in rat), May 64–72
 receptors, May 6–7
 storage, and pheochromocytoma (in rat), May 77–79
 synthesis, pathway of, May 8
 uptake, May 7–8
 urinary, and metabolites
 effects of drugs and interfering substances on, May 42
 in pheochromocytoma diagnosis, May 41–43
 Cell(s)
 endocrine, lung, terms for, July 8
 germ cell origin of tumors, Sept. 6
 Kulchitsky (*see* Kulchitsky cell)
 neuroendocrine (*see* Kulchitsky cell)
 radiation cell survival curve, Oct. 17
 stem (*see* Stem cell)
 T cell leukemia and lymphoma virus (*see* HTLV)
 tumor cell clusters, enzymes used for disintegration of, Dec. 16–17
 Central nervous system: cancer mortality, Mar. 71
 Cervical (*see* Teratoma, in infant and children, cervical)
 Cervix, cancer, Apr. 23–27
 awareness, Apr. 26–27
 incidence, Apr. 23–24
 nursing intervention, Apr. 24–27
 risk factors, Apr. 24
 signs and symptoms, Apr. 24
 Chemical carcinogenesis, Feb. 9–11
 Chemodectoma: of neck, Aug. 6
 Chemotherapy
 cancer due to (in animals), Feb. 12
 as carcinogenic, Feb. 14
 of colorectal cancer, adjuvant, Oct. 8–10
 of Kulchitsky cell cancer III, July 29
 lymphoma after, non-Hodgkin's, Feb. 30–33
 of nonmalignant disease
 cancer after, Feb. 11–14
 leukemia after, Feb. 13
 of pericardial effusion, malignant, June 40
 in pleural effusions, June 21–22
 malignant, June 19
 second cancer after, Feb. 4–43
 Chest pain: in pheochromocytoma, May 15
 Children
 AIDS of, Jan. 19–20

- Children (cont.)**
- hyperparathyroidism of, Nov. 35
 - pheochromocytoma, atypical manifestations, May 20-21
 - teratoma (*see* Teratoma, in infant and children)
- Chlorambucil:** in Hodgkin's disease, and leukemia risk, Feb. 22
- Cholelithiasis:** and pheochromocytoma, May 29
- Chromatin**
- granules and catecholamine content of tumors, May 10
 - tissue, extra-adrenal, in newborn, May 9
- Chromomycin:** and human tumor cloning assay, Dec. 19-20
- Chylopericardium:** June 27
- Chylothorax:** June 17-18
- Cimetidine:** in hyperparathyroidism, Nov. 33
- Classification**
- International Classification of Diseases,* alterations in statistics by 8th and 9th revisions of Mar. 61-77
 - morphological, Mar. 61-65
 - topographic, Mar. 61-65
- Clonidine**
- epinephrine and, May 39
 - norepinephrine and, May 39
 - suppression test in pheochromocytoma, May 38-39
- Cloning assay:** human tumor, Dec. 4-50
- abbreviations, Dec. 5
 - abrin and, Dec. 19
 - anthracenes and, Dec. 25-26
 - anthracycline-analogues and, Dec. 24
 - antitumor agents, screening for, Dec. 22-26
 - applications of, Dec. 22-34
 - breast cancer and, Dec. 30-31
 - survival, Dec. 36-38
 - breast carcinomas and, Dec. 30
 - in capillaries, Dec. 8-9
 - carminomycin and, Dec. 24-25
 - chromomycin and, Dec. 19-20
 - clinical correlations with, Dec. 26-34
 - colonies formed in, methods employed to prove malignant nature of, Dec. 11
 - colony formation
 - attempts to increase, Dec. 14-19
 - evaluation of, Dec. 19-20
- serum supplements, Dec. 14**
- single substances, Dec. 15-19
- Courtenay/Mills technique, Dec. 9**
- definitions, Dec. 5
 - drug activation and, Dec. 21-22
 - drug effects and, evaluation of, Dec. 20-21
- drug stability as problem with screening in, Dec. 21**
- early experiences, Dec. 6-7
 - future directions for, Dec. 40-41
- Hamburger/Salmon technique, Dec. 7-8**
- head cancer and, Dec. 31**
- survival, Dec. 38, 39
- histochemical studies, Dec. 10**
- interferons and, Dec. 24
 - karyotyping and, Dec. 10
 - leukemia and, Dec. 33-34
 - lung cancer and, Dec. 31-32
 - survival, Dec. 38-40
- lung carcinoma and, Dec. 32**
- m-AMSA and, Dec. 25**
- melanoma and, Dec. 32-33**
- microscopy in**
- electron, Dec. 10
 - light, Dec. 10
- modifications of, Dec. 13**
- myeloma and, multiple, Dec. 33**
- survival, Dec. 40
- neck cancer and, Dec. 31**
- survival, Dec. 38, 39
- neuroblastoma and, Dec. 40**
- ovarian cancer and, Dec. 29-30**
- survival, Dec. 34-36
- radiation and, lethal, Dec. 19**
- refrigeration and, Dec. 19**
- single cell suspensions, attempts to improve, Dec. 13-14**
- sodium azide and, Dec. 19**
- stem cell hypothesis, Dec. 5-6**
- stimulatory activity in, substances tested for, Dec. 18**
- studies on**
- heterogenous tumor types, Dec. 26-29
 - with mixed tumor populations, Dec. 27
 - on specific tumor types, Dec. 29-34
- survival and, Dec. 34-40**
- transplantation of colonies (in nude mice), Dec. 10-12**
- tumor marker studies, Dec. 10**
- tumors cloned in, Dec. 22**
- experience at San Antonio, Dec. 23

- CNS cancer mortality, Mar. 71
 Colon
 cancer (*see* Colorectal cancer)
 carcinoma (*see* Colorectal carcinoma)
 Colonies
 formation (*see* Cloning assay, human tumor, colony formation)
 formed in HTCA, methods employed to prove malignant nature of, Dec. 11
 malignant nature of, evidence for, Dec. 9-12
 transplantation, and human tumor cloning assay (in nude mice), Dec. 10-12
 Colorectal cancer, Apr. 29-35, Oct. 3-34
 adjuvant therapy of, Oct. 3-34
 rationale for, Oct. 5-7
 anticoagulants and, Oct. 10-11
 chemotherapy, adjuvant, Oct. 8-10
 Dukes classification, modified, Oct. 5
 fibrinolysis in, Oct. 10-11
 future for, Oct. 30
 growth of, biology of, Oct. 3-4
 immunotherapy of, Oct. 11
 incidence, Apr. 29-32
 nursing intervention, Apr. 34-35
 radiotherapy
 adjuvant, postoperative, Oct. 21-25
 adjuvant, preoperative, Oct. 19-21
 adjuvant preoperative and postoperative, Oct. 25-26
 "sandwich" technique, Oct. 25-26
 recurrence
 factors contributing to, Oct. 4-5
 vs. stage, Oct. 15
 risk factors, Apr. 32-33
 signs and symptoms, Apr. 33
 spread of, biology of, Oct. 3-4
 stage vs. recurrence, Oct. 15
 surgery, curative, patterns of failure after, Oct. 13-16
 survival, Oct. 7
 Colorectal carcinoma
 radiotherapy
 adjuvant, Oct. 12-13
 postoperative, results, Oct. 22
 preoperative, results, Oct. 22
 resection, local recurrence after, incidence of, Oct. 14
 Community hospital cancer programs:
- registry data from, uses of, Mar. 13-21
 Computed (*see* Tomography, computed)
 Computer programmers: for cancer center patient data system, Mar. 11-12
 Connective tissue cancer: mortality, Mar. 69
 Constipation: in pheochromocytoma, May 16
 Cornea: in multiple endocrine neoplasia, May 23
 Counseling: on sun exposure and sunscreen protection, Apr. 13
 Courtenay/Mills technique: in human tumor cloning assay, Dec. 9
 Cranium (*see* Teratoma, in infant and children, intracranial)
 Cyclophosphamide: bladder cancer after, Feb. 34-35
 Cyst: lateral cervical, Aug. 5
 Cystic neck mass: midline, Aug. 5
 Cytogenetics: of treatment-related cancer, Feb. 14-16
 Cytology: of Kulchitsky cell carcinoma, July 11

D

- Data, Mar. 7-77
 availability of, Mar. 33-38
 cancer center patient data system, Mar. 7-12
 computer programmers, Mar. 11-12
 data retrieval from clinical studies, Mar. 10-11
 file structure, data base, Mar. 9
 initial data acquisition, Mar. 7-8
 personnel for, Mar. 11-12
 project assistance, Mar. 11
 quality control, Mar. 8-9
 tumor registries, inquiries from, Mar. 10
 update at time of death, Mar. 10
 cancer data system, Mar. 7-77
 current status, Mar. 38-46
 from developing countries, Mar. 31-48
 on environmental hazards, Mar. 46
 frequency, relative, Mar. 41
 future trends for, Mar. 46-47
 mortality (*see* Mortality, data)
 nature of, Mar. 33-38
 on services, availability and utilization of, Mar. 41-46

- Data (*cont.*)
 for services evaluation, Mar. 38
 uses of, Mar. 31–32
- Death
(See also Mortality)
 registry and, Mar. 26
- Detection: of cancer, Apr. 4–42
- Developing countries: data from, Mar. 31–48
- Diarrhea: in pheochromocytoma, May 16
- Diphosphonates: in hyperparathyroidism, Nov. 34
- Diuretics: and hypercalcemia, Nov. 12
- Drugs (*see Cloning assay, human tumor, drugs*)
- Dukes classification: modified, of colorectal cancer, Oct. 5
- E**
- Echocardiography: of pericardial effusion, June 30
- Electrical alternans: ECG of, June 30
- Electrocardiography
 of electrical alternans, June 30
 in pheochromocytoma, of abnormalities, May 35–36
- Electron micrograph: of HTLV, Jan. 24
- Electron microscopy
 human tumor cloning assay and, Dec. 10
 of Kulchitsky cell carcinoma, July 12
- parameters used to consider a cell derived from a colony malignant, Dec. 12
- Embryo: dorsal and cross-sectional views, Sept. 4
- Embryology: of parathyroid, Nov. 17–23
- Endocrine
 cell, pulmonary, terms for, July 8
 multiple endocrine neoplasia (*see* Multiple endocrine neoplasia)
- Endodermal sinus tumor, Sept. 28
- Endometrium: adenocarcinoma, June 16
- Environmental factors: and cancer, Mar. 38
- Environmental hazards: data on, Mar. 46
- Enzymes
 within Kulchitsky cell cancer, July 21
 for tumor cell cluster disintegration, Dec. 16–17
- F**
- Epinephrine
 clonidine and, May 39
 pheochromocytoma and, May 40
- Esophagus: "swallowing" enlarged parathyroid, Nov. 21
- Estrogen: in hyperparathyroidism, Nov. 34
- F**
- Facial features: in multiple endocrine neoplasia, May 22
- α -Fetoprotein
 normal range, in infant, Sept. 11
 in teratoma of infant and children, Sept. 10–12
- Fever: in pheochromocytoma, May 19
- Fibrinolysis: in colorectal cancer, Oct. 10–11
- Fibroblast interferon, Dec. 24
- Food intake: and pheochromocytoma (in rat), May 74
- G**
- Gastric (*see Stomach*)
- Germ cell origin: of tumors, Sept. 6
- Gingiva: Kapozi's sarcoma of, Jan. 12
- Gonadotropin: human chorionic, in teratoma of infant and children, Sept. 12–13
- Growth: nerve growth factor, May 62–63
- H**
- Hamburger/Salmon technique: in human tumor cloning assay, Dec. 7–8
- Head cancer, and human tumor cloning assay, Dec. 31 survival, Dec. 38, 39
- Headache: in pheochromocytoma, May 13
- Heart
 rate in pheochromocytoma study (in rat), May 64
 tamponade, June 28–29
 pathophysiology, June 28–29
 teratoma (*see Teratoma, in infant and children, cardiac*)
- History: medical, and cancer risk assessment, Apr. 5–7
- Hodgkin's disease
 chlorambucil in, and leukemia risk, Feb. 22
 leukemia and, treatment-related, Feb. 18–21

- lymphoma after, non-Hodgkin's,
 clinical and pathologic findings,
 Feb. 30
 solid tumors after, Feb. 32-33
 treatment, leukemia after, acute
 nonlymphocytic, Feb. 18-21
 actuarial risk, Feb. 22
 Homosexuality: in AIDS, Jan. 15-17
 Hormones: within Kulchitsky cell
 cancer, July 21
 Hospital cancer programs, Mar.
 13-21
 approved, Mar. 17
 benefit from, evidences of, Mar.
 17-21
 characteristics of, Mar. 20
 clinical program, Mar. 13-15
 communication facilitated by, Mar.
 20
 description, Mar. 13-17
 generally recognized technology
 transfer in community, Mar. 19
 longevity of program, Mar. 19
 patient care evaluation, Mar. 15-17
 role in technology transfer, Mar. 19
 size of program, Mar. 19
 successful, Mar. 19
 survival, evaluation of, Mar. 15-17
 HTCA (*see* Cloning assay, human
 tumor)
 HTLV, Jan. 23-25
 III
 antibody-positive or -negative
 status, Jan. 29
 causality postulates, evidence for
 worldwide, Jan. 26-29
 evaluation of presence of, Jan. 27
 -positive tests, prognostic
 implications, Jan. 29-30
 vaccine preparations against,
 Jan. 32
 Hypercalcemia
 Addison's disease and, Nov. 12
 cancer and, Nov. 9-10
 crisis of, Nov. 29
 diagnosis, differential, Nov. 7-13
 arranged by approximate
 frequency, Nov. 8
 diuretics and, Nov. 12
 hyperparathyroidism in (*see*
 Hyperparathyroidism, primary,
 hypercalcemia in)
 hypocalciuric, familial, Nov. 13
 immobilization and, Nov. 12-13
 lithium and, Nov. 12
 milk-alkali syndrome and, Nov. 13
 osteolytic, local, Nov. 10
 sarcoidosis and, Nov. 10-11
 vitamin A and, Nov. 11
 vitamin D and, Nov. 11
 Hyperparathyroidism
 cancer and, Nov. 41-43
 in children, Nov. 35
 persistent, Nov. 29-31
 during pregnancy, Nov. 35-36
 primary
 adenoma and, Nov. 23-24
 "asymptomatic patients," Nov. 17
 beta-adrenergic blocking agents
 in, Nov. 33
 bone disease in, Nov. 16
 cancer and, Nov. 24-25
 cimetidine in, Nov. 33
 clinical manifestations, Nov.
 15-17
 clinical presentation, Nov. 16
 diphosphonates in, Nov. 34
 estrogen in, Nov. 34
 etiology, Nov. 14-15
 gastrointestinal manifestations,
 Nov. 16
 hypercalcemia in, Nov. 8-9
 hypercalcemia in, in impaired
 renal function, Nov. 8-9
 hypercalcemia in, in normal renal
 function, Nov. 8
 hyperplasia and, Nov. 24
 hypertension in, Nov. 16-17
 incidence, Nov. 14-15
 kidney stones in, Nov. 15-16
 medical treatment, Nov. 33-34
 MEN syndromes and, Nov. 31-32
 natural history, Nov. 13-14
 neuromuscular symptoms, Nov.
 17
 pathology, Nov. 23-25
 pernicious, Nov. 29
 phosphate in, inorganic, Nov. 33
 prevalence, Nov. 14-15
 psychiatric symptoms in, Nov. 17
 PTH antagonist in, Nov. 34
 recurrent, Nov. 29-31
 Hyperplasia
 chief cell, Nov. 24
 hyperparathyroidism and, Nov. 24
 water-clear cell, Nov. 24
 Hypertension
 in hyperparathyroidism, Nov.
 16-17
 paroxysmal, classic, radiography in,
 May 45
 in pheochromocytoma, May 14
 Hyperthyroidism: and hypercalcemia,
 Nov. 11-12
 Hypocalcemia: postoperative, Nov.
 32-33

- Hypocalciuric hypercalcemia: familial, Nov. 13
- Hypophysectomy: blood pressure and catecholamines after (in rat), May 64-72
- I
- Immobilization: and hypercalcemia, Nov. 12-13
- Immune deficiency (*see AIDS*)
- Immunosuppression: and cancer, Feb. 6-8
- Immunotherapy: of colorectal cancer, Oct. 11
- Incidence of cancer, Mar. 22-30
cumulative rate, Mar. 28
data on, discussion of, Mar. 41
evolution in five continents, Mar. 22-30
registries, Mar. 22-24
tables on, Mar. 29-30
- Infant
- adenocarcinoma of, embryonal, Sept. 28
 - alpha fetoprotein in, normal range, Sept. 11
 - teratoma (*see Teratoma, in infant*)
- Interferon
- alpha-interferon, Dec. 24
 - beta-interferon, Dec. 24
 - cloning assay and, human tumor, Dec. 24
 - fibroblast, Dec. 24
 - leukocyte, human, Dec. 24
- International Classification of Diseases:* alterations of statistics by 8th and 9th revisions of, Mar. 61-77
- Intestine
- adenocarcinoma,
radioresponsiveness of, Oct. 16-19
 - manifestations in
hyperparathyroidism, Nov. 16
- Intracranial (*see Teratoma, in infant and children, intracranial*)
- Irradiation (*see Radiation*)
- Isoproterenol: and pheochromocytoma (in rat), May 75
- K
- Kaposi's sarcoma
- in AIDS, Jan. 11-15
 - comparison of classic and aggressive variants, Jan. 13
 - of gingiva, Jan. 12
- Karyotyping: and human tumor cloning assay, Dec. 10
- Kidney
- function impairment in
hypercalcemia with
hyperparathyroidism, Nov. 8-9
 - stones in hyperparathyroidism, Nov. 15-16
- Kulchitsky cell cancer, July 3-38
biologic markers in, July 21
cases, July 14-18
clinical manifestations, July 13-23
definitions, July 3-4
diagnosis, fundamental histological, July 18-19
diagnostic challenges, July 13-20
enzymes in, July 21
epidemiology, July 9-10
the future, June 32-33
histology, July 10-12
history, July 4-10
hormones in, July 21
- I
- extent of disease, July 22
 - resection in, July 25
 - sex distribution of, July 9
 - staging, July 22
 - treatment, July 23-27
 - treatment outcome, July 26
 - paraneoplastic syndrome, July 20-21
 - presentation, July 13
- III
- chemotherapy of, July 29
 - extent of disease, July 22-23
 - intermediate type, July 12
 - surgery of, July 31-32
 - survival after, July 29
 - treatment, July 27-32
 - treatment, response rates to, July 29
- II
- extent of disease, July 22
 - resections in, July 25
 - sex distribution of, July 9
 - staging, July 22
 - treatment, July 23-27
 - treatment outcome, July 26
- Kulchitsky cell carcinoma
- cytologic characteristics, July 11
 - electron microscopy of, July 12
 - histologic characteristics, July 11
 - oat cell, July 12
- I, location of, July 14
- III, July 18
- differential diagnosis, July 15, 17
 - overlapping diagnostic features with KCC-II, July 16

- II
 differential diagnosis, July 17
 location of, July 14
 overlapping diagnostic features
 with KCC-III, July 16
 Kussmaul's sign, June 29
- L
 Laryngopharyngectomy: in pyriform sinus cancer, Aug. 29
 Law: Starling's, in fluid flow from parietal pleura to visceral pleura, June 7
 Leukemia
 acute, treatment-related, clinical features, Feb. 17
 cloning assay and, human tumor, Dec. 33-34
 nonlymphocytic, acute
 after chemotherapy for nonmalignant disease, Feb. 13
 after Hodgkin's disease treatment, Feb. 18
 after Hodgkin's disease treatment, actuarial risk, Feb. 22
 secondary, associated with ovarian cancer, and alkylating agents, Feb. 26
 treatment-related, Feb. 16-18
 risk after chlorambucil in Hodgkin's disease, Feb. 22
 treatment-related
 breast cancer and, Feb. 24
 Hodgkin's disease and, Feb. 18-21
 lymphoma and, non-Hodgkin's, Feb. 26-28
 myeloma and, Feb. 21-24
 ovarian cancer and, Feb. 24-26
 summary of, Feb. 29-30
 virus, T cell (see HTLV)
 Light microscopy
 human tumor cloning assay and, Dec. 10
 parameters used to consider a colony malignant, Dec. 12
 Lips: in multiple endocrine neoplasia, May 23
 Lithium: and hypercalcemia, Nov. 12
 Lung
 cancer, Apr. 35-37
 epithelial, histologic classification, July 7
 evolution, stem cell hypothesis of, July 8
- human tumor cloning assay and, Dec. 31-32
 human tumor cloning assay and, survival, Dec. 38-40
 incidence, Apr. 35
 Kulchitsky cell (see Kulchitsky cell cancer)
 nursing intervention, Apr. 36-37
 risk factors, Apr. 35-36
 signs and symptoms, Apr. 36
 small cell, July 4
 carcinoma
 human tumor cloning assay and, Dec. 32
 small cell (see Kulchitsky cell carcinoma, III)
 endocrine cell, terms for, July 8
 Lymph nodes: cervical, freely movable, neck dissection in, Aug. 28
 Lymphoma
 large-cell, and pleural effusion, June 16
 non-Hodgkin's
 after chemotherapy, Feb. 30-33
 after Hodgkin's disease, clinical and pathologic findings, Feb. 30
 leukemia and, treatment-related, Feb. 26-28
 virus, T cell leukemia (see HTLV)
 Lymphoproliferative disease: differential diagnosis, July 15
- M
 Malignancy (see Cancer)
 Malignant nature: of colonies, evidence for, Dec. 9-12
 m-AMSA: and human tumor cloning assay, Dec. 25
 Mediastinal teratoma, Sept. 30-33
 Medical records: literature review, Mar. 50-51
 Melanoma
 human tumor cloning assay and, Dec. 32-33
 malignant
 cells of, seen in pleural effusion, June 17
 heart covered by black nodules of, June 32
 with predictable lymphatic drainage, neck dissection in, Aug. 27
 MEN (see Multiple endocrine neoplasia)
 Mesothelioma: and pleura, June 18

- Metastases**
incidence from various malignancies, June 31
parathyroid, Nov. 43
- Microscopy**
electron (*see* Electron microscopy)
light (*see* Light microscopy)
- Milk-alkali syndrome**: and hypercalcemia, Nov. 13
- Mitoxantrone**: and human tumor cloning assay, Dec. 25
- Model**: stem cell, of normal and malignant tissues, Dec. 6
- Morbidity statistics**, Mar. 35-37
- Mortality**
(*See also* Death)
in AIDS, Jan. 6
bone cancer, Mar. 67
brain cancer, Mar. 71
for cancer in U.S., Mar. 70
with nonspecific site codes, Mar. 72
- CNS cancer**, Mar. 71
connective tissue cancer, Mar. 69
data, Mar. 39-41
availability for developing countries, Mar. 40
changes from ICD-8 to ICD-9 causing problems with, Mar. 65-73
literature review, Mar. 50
statistics, Mar. 33-35
quality indicators, Mar. 42-43
U.S., 1969-1979, Mar. 67
- Mouth** (*see* Oral)
- Multiple endocrine neoplasia**
cornea in, May 23
facial features in, May 22
hyperparathyroidism and, Nov. 31-32
lips in, May 23
pedigree in, May 22
pheochromocytoma and, May 22-26
tongue in, May 23
- Myeloma**
leukemia and, treatment-related, Feb. 21-24
multiple, and human tumor cloning assay, Dec. 33
survival, Dec. 40
- N**
- Neck**
cancer, and human tumor cloning assay, Dec. 31
survival, Dec. 38, 39
chemodectomy, Aug. 6
- cyst, lateral, Aug. 5
dissection (*see below*)
- mass**
case reports, Aug. 3-4
diagnosis, differential, discussion of, Aug. 4-6
evaluation, Aug. 6-10
examination of, physical, Aug. 7
history, Aug. 6
laboratory studies, Aug. 7
location of, Aug. 9-10
midline cystic, Aug. 5
radiography of, Aug. 7-9
recurrence, Aug. 30-31
recurrence, frequency of, Aug. 31
surgical anatomy of, Aug. 14-15
- Neck dissection**, Aug. 3-34
for cancer, Aug. 3-34
complications, Aug. 19-21
peculiar to operation itself, Aug. 20-21
- elective**, Aug. 31-32
modifications, indications for, Aug. 27
- modified**
advantages of, Aug. 28
operative technique for, description, Aug. 25-26
situations not suitable for, Aug. 29-30
steps in, Aug. 24-25
in thyroid cancer, Aug. 27
- radical**, Aug. 12-19
anesthesia for, Aug. 13-14
conduct of operation, Aug. 15-19
postoperative care on postoperative ward, Aug. 19
postoperative care in recovery room, Aug. 19
selection of patients, Aug. 13
skin incision for, Aug. 14
standard, less than a, Aug. 22-25
standard, of midline lesions, Aug. 28
standard, modifications of, Aug. 21-25
standard, modifications for freely movable nodes, Aug. 28
standard, modifications of, indications for, Aug. 26-28
standard, modifications in malignant melanoma, Aug. 27
standard, more than the, Aug. 21-22
standard, after radiotherapy, Aug. 28
standard, after radiotherapy failure, Aug. 28

- steps in, Aug. 16-17
 treatment of primary tumor, Aug. 13
 surgical anatomy of neck, Aug. 14-15
 surgical, therapeutic, development of, Aug. 10-12
Neoplasms (*see Tumors*)
Nerve growth factor, May 62-63
Nervous system: central, cancer mortality, Mar. 71
Neuroblastoma: and human tumor cloning assay, Dec. 40
Neurocrestopathy: and pheochromocytoma, May 28-29
Neuroendocrine
 cell (*see Kulchitsky cell*)
 system, diffuse, July 6
 tumors, July 4
Neurofibromatosis: and pheochromocytoma, May 26-28
Newborn: chromatin tissue in, extra-adrenal, May 9
Norepinephrine
 clonidine and, May 39
 pheochromocytoma and, May 40
 (in rat), May 73
Nurse: screening by, for cancer prevention and detection, Apr. 4-42
Nutrition: and cancer prevention, Apr. 37-39
- O
- Oral cavity cancer**, Apr. 14-17
 awareness, Apr. 16
 incidence, Apr. 14
 nursing intervention, Apr. 15-17
 risk factors, Apr. 14-15
 signs and symptoms, Apr. 15
Oral cavity: self-examination technique, Apr. 17
Orbit (*see Teratoma, in infant and children, orbital*)
Orcioblastoma, Sept. 28
Oropharyngeal (*see Teratoma, in infant and children, oropharyngeal*)
- Ovaries**
 cancer
 human tumor cloning assay and, Dec. 29-30
 human tumor cloning assay and, survival, Dec. 34-36
 leukemia and, alkylating agents in, Feb. 26
- leukemia and, treatment-related, Feb. 24-26
 carcinoma, risk of second tumors after treatment, Feb. 33
 teratoma (*see Teratoma, in infants and children, ovarian*)
- P
- Pain**
 abdomen, in pheochromocytoma, May 15
 chest, in pheochromocytoma, May 15
Pallor: in pheochromocytoma, May 19
Palpitations: in pheochromocytoma, May 15
Papanicolaou smears: abnormal, education concerning, Apr. 27
Paradoxical pulse, June 28-29
Paralysis: in retroperitoneal teratoma, Sept. 39
Parathyroid, Nov. 4-52
 anatomy by Sandström, Nov. 5-6
 angiography of, Nov. 25
 carcinoma, Nov. 36-41
 diagnosis, Nov. 37-38
 etiology, Nov. 36
 incidence, Nov. 36
 nonfunctioning, Nov. 40-41
 pathology, Nov. 38-39
 prognosis, Nov. 40
 symptoms, Nov. 37-38
 treatment, Nov. 39-40
 CT of, Nov. 25
 embryology, Nov. 17-23
 enlargement, "swallowed" by esophagus, Nov. 21
 histology of, Nov. 17-23
 history, Nov. 4-6
 localization, Nov. 18, 19-21
 macroscopic appearance, Nov. 21-22
 metastases, Nov. 43
 microscopic appearance, Nov. 22-23
 number of glands, Nov. 19
 preoperative arrangements, Nov. 26, 27
 preoperative localization, Nov. 25-26
 surgery of, Nov. 26-28
 technique, Nov. 26-28
 tumors, Nov. 4-52
 ultrasound of, Nov. 25
 unusual locations, Nov. 22
 venous sampling, selective, Nov. 25-26

- Paresthesias: in pheochromocytoma, May 16
- Parotid tumors, Aug. 6
- Patient care evaluation studies, national, Mar. 16
- data (*see Data*)
- Pericardial effusions, June 24-40
- echocardiography of, June 30
- fluid analysis in, June 27
- malignant, June 31-40
- chemotherapy of, June 40
- clinical data, June 32-34
- diagnosis, June 34
- pathogenesis, June 31-32
- prognosis, June 34-35
- radiotherapy of, June 37
- signs, June 33-34
- surgery of, June 37-40
- symptoms, June 32-33
- treatment, June 35-40
- pathophysiology, June 26-28
- pericardiocentesis in, June 35-37
- Pericardiocentesis: in pericardial effusion, June 35-37
- Pericarditis
- constrictive, June 29-30
 - radiation, June 30
- Pericardium, June 24-26
- anatomy, normal, June 25
 - effusions (*see Pericardial effusions*)
 - fluid, June 26
 - historical aspects, June 24-25
 - parietal, June 25
 - physiology, normal, June 25-26
 - sclerosis, June 37
 - teratoma, Sept. 30-33
 - visceral, June 25
 - window, subxiphoid approach to, June 38
- Phenol sulfotransferase: (in rat), May 78
- Pheochromocytoma, May 5-87
- in adrenal, angiography of, May 46
 - adrenergic blockade in, May 53-55
 - anxiety in, May 15
 - apudoma and, May 28-29
 - atypical manifestations, May 20-22
 - biochemical tests in, May 36-43
 - bladder tumor and, May 21-22
 - blood pressure in
 - alterations, May 16-19
 - (in rat), May 64-72, 73 - blood sampling in, central venous, May 50-51
 - bradycardia in, May 19
 - cAMP and (in rat), May 75
 - catecholamines in, May 508
- diagnosis, May 39-41
- metabolism (in rat), May 77-79
- (in rat), May 64-72
- storage (in rat), May 77-79
- urinary, and their metabolites in diagnosis, May 41-43
- in children, atypical manifestations, May 20-21
- cholelithiasis and, May 29
- clonidine-suppression test in, May 38-39
- constipation in, May 16
- diagnosis, May 33-51
- differential, May 29-33
 - diarrhea in, May 16
- ECG abnormalities in, May 35-36
- epinephrine and, May 40
- experimental, May 60-79
- desensitization of beta adrenergic receptors by, May 72-76
- extra-adrenal, location of, May 9
- fever in, May 19
- follow-up, May 55-58
- food intake and (in rat), May 74
- headache in, May 13
- hypertension in, May 14
- incidence, May 11-12
- isoproterenol and (in rat), May 75
- laboratory abnormalities in, May 35-36
- laboratory findings in, May 37
- location, preoperative, May 44-51
- medical management, chronic, May 58-59
- multiple endocrine neoplasia and, May 22-26
- neurocrestopathy and, May 28-29
- neurofibromatosis and, May 26-28
- norepinephrine and, May 40
- (in rat), May 73
- operative management, May 55-58
- origin of, May 8-9
- pain in, of abdomen and chest, May 15
- pallor in, May 19
- palpitations in, May 15
- paresthesias in, May 16
- pathologic entities associated with, May 22-29
- pathophysiology, May 9-11
- "pearls" concerning, May 35
- pharmacologic tests in, May 43-44
- postoperative management, May 55-58
- during pregnancy, May 21
- preoperative evaluation, May 52-55
- preoperative management, May 52-55

- presentation, clinical, May 12-22
 radiography for location of, May 44-49
 Raynaud's phenomenon in, May 19
 retinopathy in, May 19, 20
 scintigraphy of, May 49
 screening for, indications for, May 34
 signs, May 16-19
 surgical pathology, May 47
 sweating in, May 13-15
 symptoms, May 13-16
 tachycardia in, May 19
 treatment, May 51-59
 tremor in, May 19
 visual disturbance in, May 15-16
 weight loss in, May 15
 weight and (in rat), May 74
 Phosphate: inorganic, in hyperparathyroidism, Nov. 33
 Pleura, June 6-7
 anatomy, normal, June 6
 effusions (*see* Pleural effusions)
 fluid, computer printout of function studies before and after removal, June 11
 mesothelioma and, June 18
 parietal, June 6
 physiology, normal, June 6-7
 Starling's law in fluid flow from parietal pleura to visceral pleura, June 7
 visceral, June 6
 Pleural effusions, June 5-24
 clinical data on, June 9-10
 exudates, June 7
 causes of, June 8
 criteria for, June 9
 fluid analysis, June 8-9
 intrapulmonary, June 11
 malignant, June 14-24
 causes of, June 14
 chemotherapy of, June 19
 chemotherapy of, intrapleural, June 21-22
 diagnosis, June 15-18
 incidence, June 14-15
 management, June 21
 pleurectomy in, June 23-24
 pleurodesis in, June 20-21
 prognosis, June 18-19
 quinacrine in, June 22
 radioisotopes in, intrapleural, June 21
 radiotherapy in, June 19-20
 talc in, June 22-23
 tetracycline in, June 22
 thoracentesis in, June 20
 thoracoscopy in, tube, June 20
 treatment, June 19-24
 melanoma cells in, malignant, June 17
 pathophysiology, June 7-9
 radiographic findings in, June 10-13
 subpulmonic, June 11
 symptoms, June 9-10
 thoracentesis in, June 13-14
 transudates, June 7
 causes of, June 7
 in U.S., June 5
 Pleurectomy: in malignant pleural effusions, June 23-24
 Pleurodesis: in malignant pleural effusions, June 20-21
 Pneumonectomy: chest radiography after, June 13
 Pregnancy
 hyperparathyroidism during, Nov. 35-36
 pheochromocytoma during, May 21
 Prevention: of cancer, Apr. 4-42
 Programs (*see* Hospital cancer programs)
 Protein: carcinoembryonic, and teratoma, Sept. 10-13
 Pseudotumors: in pleural effusions, June 10, 12
 Psychiatric symptoms: in hyperparathyroidism, Nov. 17
 PTH antagonist: in hyperparathyroidism, Nov. 34
 Pulse: paradoxical, June 28-29
 Pyriform sinus: cancer, laryngopharyngectomy for, Aug. 29

Q

- Quality control: in cancer registration programs, Mar. 49-80
 Quinacrine: in malignant pleural effusions, June 22

R

- Radiation
 (*See also* Radiography, Radiotherapy)
 cancer due to, Feb. 8-9
 cell survival curve, Oct. 17
 lethal, and human tumor cloning assay, Dec. 19
 pericarditis, June 30
 second cancer after, Feb. 35-37

- Radiography
 chest, after pneumonectomy, June 13
 in hypertension, classic paroxysmal, May 45
 in pheochromocytoma location, May 44-49
 in pleural effusions, June 10-13
 of retroperitoneal teratoma, benign, Sept. 38
- Radioisotopes: intrapleural, in malignant pleural effusions, June 21
- Radioresponsiveness
 of adenocarcinoma of intestine, Oct. 16-19
 discussion of term, Oct. 18
- Radiotherapy
 of colorectal cancer (*see* Colorectal cancer, radiotherapy)
 of colorectal carcinoma (*see* Colorectal carcinoma, radiotherapy of)
 failure, neck dissection after, Aug. 28
 neck dissection after, Aug. 28
 of pericardial effusion, malignant, June 37
 in pleural effusion, malignant, June 19-20
 of rectal carcinoma (*see* Rectum, carcinoma, radiotherapy of)
- Raynaud's phenomenon: in pheochromocytoma, May 19
- Rectum
 cancer (*see* Colorectal cancer)
 carcinoma
 (*See also* Colorectal carcinoma)
 radiotherapy of, adjuvant, Oct. 12-13
 radiotherapy as primary treatment, Oct. 28-29
 unresectable, preoperative radiotherapy, Oct. 26-28
- Refrigeration: and human tumor cloning assay, Dec. 19
- Registration: reliability of, Mar. 26-28
- Registry
 abstracting for, Mar. 51-53
 central, Mar. 55-56
 abstracting for, Mar. 55-56
 ascertainment of cases, Mar. 55
 coding for, Mar. 56
 follow-up, Mar. 56
 coding for, Mar. 51-53
 data from community hospital cancer programs, uses of, Mar. 13-21
- death certificate only, Mar. 26
deaths in period, Mar. 26
on five continents, Mar. 22-24
histologic verification for, Mar. 26
hospital, Mar. 53-55
 abstracting for, Mar. 54
ascertainment of reportable cases, Mar. 53-54
coding for, Mar. 54
follow-up Mar. 54
inquiries from, to cancer center
 patient data system, Mar. 10
providing data for cancer incidence in five continents, Mar. 44-45
quality control in registration programs, Mar. 49-60
literature review, Mar. 49-53
problems in quality control, sources of, Mar. 53-56
quality of data assessment, procedures for, Mar. 56-57
- Renal (*see* Kidney)
- Resources: statistics on availability and use of, Mar. 37
- Retinopathy: in pheochromocytoma, May 19, 20
- Retroperitoneal (*see* Teratoma, in infant and children, retroperitoneal)
- S
- Sacrococcygeal (*see* Teratoma, in infant and children, sacrococcygeal)
- "Sandwich" technique: in radiotherapy of colorectal cancer, Oct. 25-26
- Sarcoidosis: and hypercalcemia, Nov. 10-11
- Sarcoma (*see* Kaposi's sarcoma)
- Scintigraphy: of pheochromocytoma, May 49
- Sclerosis: pericardial, June 37
- Screening: by nurse clinician in cancer prevention and detection, Apr. 4-42
- Services
 availability and use of, data on, Mar. 41-46
 data for evaluation of, Mar. 38
- Sex
 in AIDS, Jan. 6
 distribution of Kulchitsky cell cancers, July 9
- Sinus tumor: endodermal, Sept. 28
- Skin
 cancer, Apr. 7-14
 incidence, Apr. 7

- nursing intervention, Apr. 12-14
 risk factors, Apr. 12
 signs and symptoms, Apr. 12
- Smoking: cessation of, Apr. 37
- Sodium azide: and human tumor cloning assay, Dec. 19
- Solid tumors (see Tumors, solid)
- Starling's law: in fluid flow from parietal pleura to visceral pleura, June 7
- Statistics
 alterations by 8th and 9th revisions of *International Classification of Diseases*, Mar. 61-77
 on cancer occurrence, Mar. 33
 morbidity, Mar. 35-37
 mortality, Mar. 33-35
 quality indicators, Mar. 42-43
 on resources, availability and use of, Mar. 37
- Stem cell hypothesis
 human tumor cloning assay and, Dec. 5-6
 of lung cancer evolution, July 8
 model of normal and malignant tissues, Dec. 6
- Stomach
 manifestations in hyperparathyroidism, Nov. 16
 teratoma (see Teratoma, in infant and children, gastric)
- Stones: renal, in hyperparathyroidism, Nov. 15-16
- Stool occult blood testing, Apr. 34
- Sun exposure: counseling on, Apr. 13
- Sunscreen protection: counseling on, Apr. 13
- Surveillance: in cancer center patient data system, Mar. 9-10
- Survival rates: by site or disease and geographic region, Mar. 17
- Sweating: in pheochromocytoma, May 13-15
- T
- Tachycardia: in pheochromocytoma, May 19
- Talc: in malignant pleural effusions, June 22-23
- Tamponade, cardiac, June 28-29
 pathophysiology, June 28-29
- T cell leukemia and lymphoma virus (see HTLV)
- Teratoma, in infant and children, Sept. 3-53
 alpha fetoprotein and, Sept. 10-12
- carcinoembryonic proteins and, Sept. 10-13
 cardiac, Sept. 46
 preoperative evaluation, Sept. 46
 therapy, Sept. 46
- cervical, Sept. 33-36
 operative technique, Sept. 35-36
 preoperative evaluation, Sept. 35
- gastric, Sept. 36-37
 benign, Sept. 36
 follow up, Sept. 37
 operative therapy, Sept. 37
 preoperative evaluation, Sept. 37
- gonadotropin and, human chorionic, Sept. 12-13
- histology, Sept. 6-10
- intracranial, Sept. 40-43
 preoperative evaluation, Sept. 41-42
 therapy, Sept. 42-43
- malignant, therapy, Sept. 13-16
- mediastinal, Sept. 30-33
- orbital, Sept. 45-46
 preoperative evaluation, Sept. 45-46
 therapy, Sept. 46
- opharyngeal, Sept. 43-45
 preoperative evaluation, Sept. 44
 therapy, Sept. 44-45
- ovarian, Sept. 23-27
 benign, Sept. 24
 bilateral in, incidence of, Sept. 27
 immature, comparison of grade and stage with survival, Sept. 26
 immature, Norris classification system, Sept. 25
 preoperative evaluation, Sept. 26
 therapy, Sept. 26-27
- pericardial, Sept. 30-33
- retroperitoneal, Sept. 37-40
 benign, radiography of, Sept. 38
 malignant, with paralysis, Sept. 39
 preoperative evaluation, Sept. 38-39
 therapy, Sept. 39-40
- sacrococcygeal, Sept. 16-23
 adjunctive therapy, Sept. 23
 arteriography of, Sept. 21
 classification system, Sept. 17
 histologic findings, Sept. 9
 operative technique, Sept. 21-23
 preoperative evaluation, Sept. 19-20
 presentations, diverse, Sept. 18
 surgical approach after Hendren and Henderson, Sept. 22

- Teratoma (*cont.*)
 site, distribution by, Sept. 5
 testicular, Sept. 28-30
 preoperative evaluation, Sept. 28
 therapy, Sept. 28-30
 vaginal, Sept. 45
 preoperative evaluation, Sept. 45
 therapy, Sept. 45
- Testes
 cancer, Apr. 27-29
 awareness, Apr. 30-31
 nursing intervention, Apr. 29
 risk factors, Apr. 28
 signs and symptoms, Apr. 28-29
 self examination, Apr. 31
 teratoma (*see Teratoma, in infant and children, testicular*)
- Tetracycline: in malignant pleural effusions, June 22
- Thoracentesis in pleural effusion, June 13-14
- malignant, June 20
- Thoracoscopy: tube, in malignant pleural effusions, June 20
- Thyroid carcinoma, neck dissection in, Aug. 27
- modifications of, Aug. 26
- Tomography, computed
 of parathyroid, Nov. 25
 of teratoma, mediastinal, Sept. 33
- Tongue: in multiple endocrine neoplasia, May 23
- Transplantation: of colony, and human tumor cloning assay (in nude mice), Dec. 10-12
- Tremor: in pheochromocytoma, May 19
- Tumors
 in AIDS, Jan. 14
 bladder, and pheochromocytoma, May 21-22
 carcinoid, July 3
(See also Kulchitsky cell cancers I and II)
 cell clusters, enzymes used for disintegration of, Dec. 16-17
 cloning assay (*see Cloning assay, human tumor*)
 codes for, in *International Classification of Diseases*. Mar. 62
- colony formed in capillary system, Dec. 9
- endodermal sinus, Sept. 28
- of germ cell origin, Sept. 6
- marker studies and human tumor cloning assay, Dec. 10
- multiple endocrine neoplasia (*see Multiple endocrine neoplasia*)
- neuroendocrine, July 4
- parathyroid, Nov. 4-52
- parotid, Aug. 6
- solid
 after Hodgkin's disease, Feb. 32-33
 after primary cancer, Feb. 33-34
 vanishing, in pleural effusions, June 10
- U
- Ultrasonography: of parathyroid, Nov. 25
- V
- Vaccine preparations: against HYLV III, Jan. 32
- Vagina (*see Teratoma, in infant and children, vaginal*)
- Venous sampling: in parathyroid, Nov. 25-26
- Virus(es)
 AIDS due to, probable, isolation of, Jan. 22-25
 cancer associated, Feb. 7
 T cell leukemia and lymphoma (*see HTLV*)
- Visual disturbance: in pheochromocytoma, May 15-16
- Vitamin A
 excess, Nov. 11
 hypercalcemia and, Nov. 11
- D, and hypercalcemia, Nov. 11
- W
- Weight in pheochromocytoma, May 15
 (in rat), May 64, 74

